Literature DB >> 23861505

Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study.

Michael M Givertz1, Douglas L Mann, Kerry L Lee, Jenny C Ibarra, Eric J Velazquez, Adrian F Hernandez, Alice M Mascette, Eugene Braunwald.   

Abstract

Entities:  

Keywords:  allopurinol; clinical trial; heart failure; xanthine oxidase

Mesh：

Substances：

Year:  2013        PMID： 23861505      PMCID： PMC3902033          DOI： 10.1161/CIRCHEARTFAILURE.113.000394

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN： 1941-3289            Impact factor:   8.790


× No keyword cloud information.
  43 in total

1.  Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris.

Authors:  Narasimharajapura S Rajendra; Sheila Ireland; Jacob George; Jill J F Belch; Chim C Lang; Allan D Struthers
Journal:  J Am Coll Cardiol       Date:  2011-08-16       Impact factor: 24.094

2.  Allopurinol a new anti-ischemic role for an old drug.

Authors:  Peter H Stone
Journal:  J Am Coll Cardiol       Date:  2011-08-16       Impact factor: 24.094

3.  Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts.

Authors:  Glenn A Hirsch; Paul A Bottomley; Gary Gerstenblith; Robert G Weiss
Journal:  J Am Coll Cardiol       Date:  2012-02-28       Impact factor: 24.094

4.  Multiple biomarkers for risk prediction in chronic heart failure.

Authors:  Bonnie Ky; Benjamin French; Wayne C Levy; Nancy K Sweitzer; James C Fang; Alan H B Wu; Lee R Goldberg; Mariell Jessup; Thomas P Cappola
Journal:  Circ Heart Fail       Date:  2012-02-23       Impact factor: 8.790

5.  Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival.

Authors:  Israel Gotsman; Andre Keren; Chaim Lotan; Donna R Zwas
Journal:  J Card Fail       Date:  2012-08-03       Impact factor: 5.712

6.  Gout, allopurinol use, and heart failure outcomes.

Authors:  George Thanassoulis; James M Brophy; Hugues Richard; Louise Pilote
Journal:  Arch Intern Med       Date:  2010-08-09

Review 7.  A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.

Authors:  Jeannie Chao; Robert Terkeltaub
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

8.  Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial.

Authors:  Awsan Noman; Donald S C Ang; Simon Ogston; Chim C Lang; Allan D Struthers
Journal:  Lancet       Date:  2010-06-09       Impact factor: 79.321

9.  Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.

Authors:  Kazuhide Ogino; Masahiko Kato; Yoshiyuki Furuse; Yoshiharu Kinugasa; Katsunori Ishida; Shuichi Osaki; Toru Kinugawa; Osamu Igawa; Ichiro Hisatome; Chiaki Shigemasa; Stefan D Anker; Wolfram Doehner
Journal:  Circ Heart Fail       Date:  2009-11-20       Impact factor: 8.790

10.  Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.

Authors:  Joshua M Hare; Brian Mangal; Joanne Brown; Charles Fisher; Ronald Freudenberger; Wilson S Colucci; Douglas L Mann; Peter Liu; Michael M Givertz; Richard P Schwarz
Journal:  J Am Coll Cardiol       Date:  2008-06-17       Impact factor: 24.094
View more
  14 in total

1.  Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.

Authors:  Seoyoung C Kim; Sebastian Schneeweiss; Niteesh Choudhry; Jun Liu; Robert J Glynn; Daniel H Solomon
Journal:  Am J Med       Date:  2015-02-03       Impact factor: 4.965

Review 2.  Association between smoking and gout: a meta-analysis.

Authors:  Yongho Jee; Christina Jeon; Jae Woong Sull; Eunna Go; Sung Kweon Cho
Journal:  Clin Rheumatol       Date:  2018-04-26       Impact factor: 2.980

3.  Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.

Authors:  Michael M Givertz; Kevin J Anstrom; Margaret M Redfield; Anita Deswal; Haissam Haddad; Javed Butler; W H Wilson Tang; Mark E Dunlap; Martin M LeWinter; Douglas L Mann; G Michael Felker; Christopher M O'Connor; Steven R Goldsmith; Elizabeth O Ofili; Mitchell T Saltzberg; Kenneth B Margulies; Thomas P Cappola; Marvin A Konstam; Marc J Semigran; Steven E McNulty; Kerry L Lee; Monica R Shah; Adrian F Hernandez
Journal:  Circulation       Date:  2015-04-14       Impact factor: 29.690

Review 4.  Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and design.

Authors:  Rosita Zakeri; James A Levine; Gabriel A Koepp; Barry A Borlaug; Julio A Chirinos; Martin LeWinter; Peter VanBuren; Victor G Dávila-Román; Lisa de Las Fuentes; Prateeti Khazanie; Adrian Hernandez; Kevin Anstrom; Margaret M Redfield
Journal:  Circ Heart Fail       Date:  2015-01       Impact factor: 8.790

Review 5.  Biomarkers of Oxidative Stress Tethered to Cardiovascular Diseases.

Authors:  Poojarani Panda; Henu Kumar Verma; Saikrishna Lakkakula; Neha Merchant; Fairrul Kadir; Shamsur Rahman; Mohammad Saffree Jeffree; Bhaskar V K S Lakkakula; Pasupuleti Visweswara Rao
Journal:  Oxid Med Cell Longev       Date:  2022-06-24       Impact factor: 7.310

Review 6.  Incorporating common biomarkers into the clinical management of heart failure.

Authors:  Meghana Halkar; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2013-12

7.  Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.

Authors:  MaryAnn Zhang; Daniel H Solomon; Rishi J Desai; Eun Ha Kang; Jun Liu; Tuhina Neogi; Seoyoung C Kim
Journal:  Circulation       Date:  2018-09-11       Impact factor: 29.690

8.  Associations of methyl donor and methylation inhibitor levels during anti-oxidant therapy in heart failure.

Authors:  Jacob Joseph; Anna Giczewska; Brooke Alhanti; Amrita K Cheema; Diane E Handy; Douglas L Mann; Joseph Loscalzo; Michael M Givertz
Journal:  J Physiol Biochem       Date:  2021-02-17       Impact factor: 4.158

9.  Pharmacological interventions for heart failure in people with chronic kidney disease.

Authors:  Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani
Journal:  Cochrane Database Syst Rev       Date:  2020-02-27

10.  Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study.

Authors:  Tanya Keenan; Wei Zhao; Asif Rasheed; Weang K Ho; Rainer Malik; Janine F Felix; Robin Young; Nabi Shah; Maria Samuel; Nasir Sheikh; Megan L Mucksavage; Omar Shah; Jin Li; Michael Morley; Annika Laser; Nadeem Hayat Mallick; Khan Shah Zaman; Mohammad Ishaq; Syed Zahed Rasheed; Fazal-Ur-Rehman Memon; Faisal Ahmed; Bashir Hanif; Muhammad Shakir Lakhani; Muhammad Fahim; Madiha Ishaq; Naresh Kumar Shardha; Naveeduddin Ahmed; Khalid Mahmood; Waseem Iqbal; Saba Akhtar; Rabia Raheel; Christopher J O'Donnell; Christian Hengstenberg; Winifred März; Sekar Kathiresan; Nilesh Samani; Anuj Goel; Jemma C Hopewell; John Chambers; Yu-Ching Cheng; Pankaj Sharma; Qiong Yang; Jonathan Rosand; Giorgio B Boncoraglio; Shahana Urooj Kazmi; Hakon Hakonarson; Anna Köttgen; Andreas Kalogeropoulos; Philippe Frossard; Ayeesha Kamal; Martin Dichgans; Thomas Cappola; Muredach P Reilly; John Danesh; Daniel J Rader; Benjamin F Voight; Danish Saleheen
Journal:  J Am Coll Cardiol       Date:  2016-02-02       Impact factor: 24.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.